A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

The decision came in response to a February lawsuit from a compounding industry group against the FDA's decision that there ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Novo Nordisk (NVO) announced on Friday that it has secured a legal victory against compounders selling unauthorized versions ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

Recent consumer research by product development group AMC Global and OpinionRoute, LLC reveals the evolving preferences of ...

See the following table for a list ... and Wegovy have a boxed warning about the risk of thyroid tumors and thyroid cancer. A boxed warning is the most serious warning from the Food and Drug ...

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

A Kentucky doctor faces up to three years in prison after admitting he sold patients a non-approved weight-loss drug. Matthew ...

The molecule is semaglutide, and it's sold under the name Ozempic for type 2 diabetes and Wegovy for weight loss ... these ...